MindFuel Blog

Unlocking the Therapeutic Potential of Psilocybin: Insights from Dr. Andrew Huberman's Latest Podcast Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. It has been used for centuries in various spiritual and cultural contexts, but in recent years, it has gained attention for its therapeutic potential in treating mental health disorders such as depression, anxiety, and...

In collaboration with the most progressive marae he could find, entrepreneur Manu Caddie has been investigating the potential of Weraroa (Psilocybe weraroa), an indigenous magic mushroom known to contain psilocybin, to support Whanau addicted the meth (methamphetamine, speed, P).

Fantastic news from our friends across the ditch: From July, authorized Australian psychiatrists will be able to prescribe the MDMA and Psilocybin (the active ingredient in magic mushrooms) for post-traumatic stress disorder (PTSD) and severe depression.

The New Zealand Drug foundation says it's "shocking" that 90 charges have been laid for magic mushroom possession in five years given the drug's relatively low harm profile.

An analysis of a large international drug survey suggests that psilocybin, one of the active ingredients in Magic Mushrooms is a relatively safe drug, with only 0.2% of magic mushroom users having sought emergency medical care after use. The findings, published in the Journal of Psychopharmacology, further suggest that such adverse incidents are most often psychological in nature and resolved within 24...

British start up Clerkenwell Health have opened Europe's first commercial facility for psychedelic drug trials with the goal of making the United Kingdom a global leader in psychedelic research and innovation.They aim to begin clinical trials at their central London facility in August, initially focusing on psilocybin for anxiety associated with diagnoses of terminal illness. Here at MindFuel we wish...

Oregon will legalise psilocybin therapy in 2023. This is what we know so far about the proposed new rules regarding magic mushroom cultivation. Suppliers will not be permitted to create psilocybin synthetically or by using GMOs All psilocybin products must be stored in a locked area and be entered into the state’s Psilocybin Tracking System. Residents will be able to...

This year, four Australian institutions will start recruiting for separate research into using psilocybin and MDMA for PTSD, addiction, depression and anxiety.Edith Cowan and Monash universities will begin separate trials into the potential for MDMA to treat post-traumatic stress disorder. St Vincent's Hospital Sydney will examine the impact of psilocybin on preventing methamphetamine relapse, Monash will study its effect on...

A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin found in so called 'Magic Mushrooms' can reduce migraine frequency by 50 percent for a least two weeks. The preliminary trial was small, with follow-up work necessary to validate the results, but the promising findings suggest great potential for...

Less than two years ago, the amazing scientists at the Johns Hopkins Psychedelic Research Unit began studying the effects of Psilocybin, one of the main psychoactive substances found in magic mushrooms. The preliminary results are out: 83% of their participants showed a clinically significant reduction in depression symptoms 53% met criteria for remission. Stay tuned for the results of their...

If phase III clinical trials are successful, researchers recommend reclassification of the drug psilocybin (which is found in magic mushrooms) from Class A to schedule IV in the USA, which is roughly the equivalent to Class C in New Zealand. Scientists studying psilocybin suggest removing the psychedelic substance from the most restrictive legal category (the equivalent of Class A in...